Alongside this evidence of Dupilumab's effectiveness in the treatment of severe asthma, only limited data exist about switching from a previous monoclonal antibody therapy to an anti-IL-4/13 biologic, and all the available information comes from real-life studies. The gene discussed is IL4; the disease is asthma.